Related Experiment Video
Updated: Jun 28, 2025
04:47
Author Spotlight: Evaluating Traditional Chinese Therapy for Ankylosing Spondylitis in Mice
Published on: October 27, 2023
952
Past, Present, and Future in Dermatomyositis Therapeutics
Melody P Chung1, Julie J Paik1
1Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Current Treatment Options in Rheumatology
|April 23, 2024
Summary
This review summarizes emerging pharmacologic therapies for dermatomyositis (DM). Recent advancements include FDA-approved IVIg and ongoing trials for JAK inhibitors, T-cell blockers, and other novel treatments, expanding therapeutic options for DM patients.
Area of Science:
- Rheumatology
- Dermatology
- Pharmacology
Background:
- Dermatomyositis (DM) is a rare autoimmune disease requiring effective treatment options.
- Current therapeutic strategies for DM are evolving with new research.
Purpose of the Study:
- To review current and emerging pharmacologic therapies for dermatomyositis.
- To summarize clinical evidence and ongoing trials for DM treatments.
Main Methods:
- Literature review of current clinical evidence.
- Summary of recently published and ongoing clinical trials for DM drugs.
Main Results:
- The FDA approved Octagam® 10% Immune Globulin Intravenous (IVIg) for DM treatment.
- JAK inhibitors (tofacitinib, baricitinib) and abatacept are key targets in phase 2/3 trials.
- Trials are exploring novel pathways: immunoproteasome inhibitors, anti-B cell therapy, anti-interferon, complement inhibitors, and PDE4 inhibitors.
Conclusions:
- Significant progress in DM treatment research is evident.
- The DM treatment landscape is rapidly evolving with numerous novel therapeutics in development.
- Improved classification and outcome measures will aid future treatment strategies.
Related Concept Videos
01:29Inflammatory Bowel Disease IV: Pharmacological Management
127
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
127
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
160
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
160
01:20Myasthenia Gravis: Overview and Treatment
1.4K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.4K
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
134
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
134
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
116
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
116
01:20The JAK-STAT Signaling Pathway
8.8K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.8K